In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genomics Squatter

Executive Summary

Armed with a purification technology it uses to isolate human DNA from the much more abundant nonhuman DNA found in stool samples, Exact Sciences is taking already-known disease-associated genomics markers into the clinical diagnostics setting. With the May announcement of the availability of its first test, for a rare form of colorectal cancer, the company is gaining visibility and traction.

You may also be interested in...



Exact Sciences Buys Time with Genzyme Deal

On the heels of its rejection of a buyout from Sequenom, Exact Sciences announced a $24.5 million IP licensing deal with Genzyme. The transaction effectively halted Sequenom's takeover effort and bought Exact time for clinical development of a next-generation version of its stool-based colorectal cancer screening test. It'sa hefty deal, but Exact's path to sustainability remains problematic.

Exact Sciences' Moment

Exact Sciences and its distribution partner, LabCorp are on the verge of launching a new molecular test for colon cancer screening. They've taken deal-making in diagnostics to a new level, but now they have to deliver on their promises.

Exact Sciences' Moment

Exact Sciences and its distribution partner, LabCorp are on the verge of launching a new molecular test for colon cancer screening. They've taken deal-making in diagnostics to a new level, but now they have to deliver on their promises.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel